Ambry Genetics has introduced Ambryscreen, a genetic screening test used to identify carriers of severe and common childhood diseases affecting pan-ethnic populations.
Ambryscreen was launched at the American College of Obstetricians and Gynecologists annual clinical meeting.
The panel is described as a responsible and ethical means of identifying individuals at high risks to have a child with severe genetic conditions.
As with all clinical assays performed by Ambry Genetics, the test must be ordered by a physician; it is not available direct to consumer.
The Ambryscreen test screens for more than 90 childhood onset conditions representing only severe or common diseases.
The core of the Ambryscreen test is a highly sensitive cystic fibrosis carrier mutation panel.
It was designed by coupling the public databases of information along with Ambry's database of more than 25,000 patients sequenced in the last decade.
The company's mutation panel includes only well-defined disease-causing mutations, without containing mild CF mutations.
